# NIH grant: SnoRNA targetome and application to cancer (1R33CA309701-01) — retained record

> Retained us-gov-api record from us-gov-api:nih-reporter.

Canonical: https://highsignal.app/data/records/39984d52d783af41

[← sources](https://highsignal.app/data)


source: [us-gov-api](https://highsignal.app/data/us-gov-api) (us-gov-api:nih-reporter)  published 2026-08-01 00:00 ingested 2026-08-03 09:17

[original source ↗](https://reporter.nih.gov/project-details/1R33CA309701-01)

## retained text



```
NIH grant 1R33CA309701-01: SnoRNA targetome and application to cancer
Institute: {'code': 'CA', 'abbreviation': 'NCI', 'name': 'National Cancer Institute', 'admin_org_id': '12500008', 'admin_funding_url': ''}. PI: CHUAN  HE. Award: $388234.
Start: 2026-08-01T00:00:00.
Project Summary
Most effective tumor treatments target multiple cellular mechanisms. This proposal will develop a new
sequencing technology to study RNA-RNA interactome and explore a previously under-appreciated cellular
mechanism in cancer biology. Small nucleolar RNA (snoRNA) is a family of small non-coding RNA that play
important roles in tumorigenesis and clinical prognosis. Recent studies indicate their diverse regulatory functions
in cancer biology including their contributions to tumor initiation, progression, and metastasis. Our goal is to
study the previously unappreciated functional diversity of snoRNAs in cancer using advanced RNA-RNA
interactome technologies. However, this application has thus far been bottlenecked by limited technology to
identify snoRNA targets at the transcriptome scale, especially for lowly abundant snoRNAs. To overcome these
barriers, we will develop new capabilities and sensitivity to our newly developed technology called snoRNA-
enriched kethoxal-assisted RNA-RNA sequencing (snoKARR-seq) to enable transcriptome-wide identification of
snoRNA targets. Aim 1 will vastly enhance the sensitivity and resolution of snoKARR-seq to identify low-
abundance snoRNA targets in cancer using mutation profiling and snoRNA-specific priming and amplification
strategies. Aim 2 will construct a comprehensive pan-cancer atlas of snoRNA targets across many types of
cancer cells, creating a foundational resource for studying the role of snoRNAs in cancer biology. Our study
represents a transformative advance in the RNA cancer biology by enabling comprehensive transcriptome-wide
mapping of snoRNA targets that provides an unprecedented level of information to address basic and clinical
questions regarding how snoRNA-target interactions can be manipulated for cancer treatment and diagnosis.
```



document fetched 2026-08-09 06:52